February 2013Welcome to the February issue of Innovations in Clinical Neuroscience. We start this issue with a study by Shiovitz et al in which the authors report the results of the first 1,132 subjects in a pilot project where local central nervous system (CNS) trial sites collaborated in the use of a subject database to identify potential duplicate subjects. The authors found that the use of a clinical trial subject registry and cooperation between CNS trial sites can reduce the number of duplicate and professional subjects entering clinical trials. The authors note, however, that to be fully effective, a trial subject database would need to be integrated into protocols across pharmaceutical companies, thereby mandating site participation and increasing the likelihood that duplicate subjects will be removed before they enter (and negatively affect) clinical trials.

Next, in this month’s installment of Psychotherapy Rounds, Gentile et al review the clinical, phenomenological, and epidemiological data regarding dissociative disorders in general, and illustrate possible treatment interventions for dissociative identity disorder in particular. Using composite case examples, the authors focus on psychotherapy interventions and review current psychopharmacology recommendations as part of a comprehensive multidisciplinary treatment plan for this somewhat controversial diagnosis.

Following this, Guerdjikova and McElroy describe a case of a young woman with bulimia nervosa, bipolar I disorder, cocaine and alcohol dependence, attention-deficit hyperactivity disorder, and panic disorder who achieved a sustained (>1 year) remission of her bulimia nervosa symptoms and significant improvement of her attention-deficit hyperactivity disorder symptoms with adjunctive methylphenidate after her bipolar, substance use, and panic disorders were successfully treated with hospitalization, intensive psychotherapy, quetiapine, and lamotrigine.

And finally, we are also pleased to include several interesting letters to the editor: two brief case reports of “bath salts” intoxication (mixed with marijuana and mixed into a beverage) as well as an enlightening exchange between author and reader regarding a recently published article on a case of risperidone-induced prolactinoma.

We hope you enjoy the issue. As always, we welcome your comments and submissions.